1. 230POlaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort. (24th November 2019) Authors: Wu, L; Zhu, J; Yin, R; Wu, X; Lou, G; Wang, J; Gao, Y; Kong, B; Lu, X; Zhou, Q; Wang, Y; Chen, Y; Lu, W; Li, W; Cheng, Y; Liu, J; Ma, X; Zhang, J Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial. (13th November 2020) Authors: Wu, X; Xia, L; Zhou, Q; Zhu, J; Wang, K; Chen, J; Huang, Y; Kurb, G; Chang, B; Zhao, W; Wang, X; Yang, Y; Lin, Z; Luo, X; Lou, G; Wang, C; Wang, J; Meng, H Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 412 T helper cell 17 is inversely related to clinical outcome to neoadjuvant chemotherapy in ovarian cancer. (13th November 2020) Authors: Lou, G; Xia, B; Xie, H; Zhang, Y; Zhang, J; Fang, L; Mao, B; Zhang, H Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗